SCHEMBL7690701

SCHEMBL7690701

Cc1ccc2nc(COc3ccc(Cl)cc3)[nH]c2c1CCCC1CCN(C(=O)CCCc2c[nH]c3ccccc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNKS O95271 6/20 0.46
PARP2 Q9UGN5 6/20 0.46
PARP1 P09874 5/20 0.46
ALDH1A1 P00352 5/20 0.44
NPY1R P25929 3/20 0.42
ACHE P22303 2/20 0.40
BCHE P06276 1/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 2/20 0.39
PKM P14618 1/20 0.39
GLA P06280 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7690696 0.79 ALDH1A1 (0.47) TNKSPARP2PARP1ALDH1A1NPY1R
SCHEMBL7966182 0.78 NPY1R (0.69) NPY1R
SCHEMBL7688416 0.75 NPY1R (0.70) NPY1R
SCHEMBL8555618 0.75 NPY1R (0.46) NPY1RACHEBCHE
SCHEMBL7688414 0.72 NPY1R (0.51) ALDH1A1NPY1RMAPTSMN1; SMN2GLA
SCHEMBL11240335 0.70 ALDH1A1 (0.66) ALDH1A1ACHEHPGDKDM4EMAPT
SCHEMBL8554479 0.69 NPY1R (0.45) ALDH1A1NPY1RMAPTLMNAKMT2A
SCHEMBL7686457 0.68 CHEK2 (0.45) BCHE
SCHEMBL6354128 0.67 SLC6A4 (0.64) ALDH1A1ACHEBCHEKMT2A
SCHEMBL7682950 0.67 NPY1R (0.75) NPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists BRITTON THOMAS CHARLES (US) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists NPY1R, NPY2R, NPY5R TNKS 2132/4885PARP2 3621/4885PARP1 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.